Literature DB >> 20665389

Immunologic response of sarcoidosis.

Gernot Zissel1, Antje Prasse, Joachim Müller-Quernheim.   

Abstract

Sarcoidosis is a chronic granulomatous disorder characterized by an accumulation of T lymphocytes, macrophages, and immune-effector cells within affected organs. The pathogenesis of sarcoidosis involves a complex interplay between immune and nonimmune cells, with myriad cytokines and chemokines involved in the orchestration and evolution of the granulomatous/fibrotic process. The etiology of sarcoidosis is not known, but a granulomatous response to antigen(s) is likely. Genetic polymorphisms influence the susceptibility to sarcoidosis as well as the evolution/prognosis of the disease among patients with sarcoidosis. This article discusses the complex immunological events and immune effector cells that are critical to the induction, evolution, and resolution of the sarcoid granulomatous response. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665389     DOI: 10.1055/s-0030-1262208

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  34 in total

Review 1.  Sarcoidosis--scientific progress and clinical challenges.

Authors:  Edward S Chen; David R Moller
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

Review 2.  Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?

Authors:  Benjamin Stump; Ye Cui; Pranav Kidambi; Anthony M Lamattina; Souheil El-Chemaly
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

3.  In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.

Authors:  M Terčelj; S Stopinšek; A Ihan; B Salobir; S Simčič; B Wraber; R Rylander
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

4.  Severe hypercalcaemia due to subcutaneous fat necrosis: presentation, management and complications.

Authors:  Daniel E Shumer; Vidhu Thaker; George A Taylor; Ari J Wassner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2014-06-06       Impact factor: 5.747

5.  [Genetic risk profile of sarcoidosis].

Authors:  A Fischer; G Zissel; A Nebel; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

6.  Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression.

Authors:  Bradley W Richmond; Kristen Ploetze; Joan Isom; Isfahan Chambers-Harris; Nicole A Braun; Thyneice Taylor; Susamma Abraham; Yolanda Mageto; Dan A Culver; Kyra A Oswald-Richter; Wonder P Drake
Journal:  J Clin Immunol       Date:  2012-10-18       Impact factor: 8.317

Review 7.  New molecular targets for the treatment of sarcoidosis.

Authors:  Jared Chiarchiaro; Bill B Chen; Kevin F Gibson
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

Review 8.  [Sarcoidosis].

Authors:  B C Frye; J C Schupp; T C Köhler; R E Voll; J Müller-Quernheim
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

9.  Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Authors:  M I Gabrilovich; J Walrath; J van Lunteren; D Nethery; M Seifu; J A Kern; C V Harding; L Tuscano; H Lee; S D Williams; W Mackay; J F Tomashefski; R F Silver
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

10.  [Granulomatous lung and systemic diseases].

Authors:  A Prasse; G Kayser; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.